Amissa

amissa.com

Over 50 million women in the United States are navigating menopause, yet the healthcare system lacks the infrastructure to manage the complexity of this stage of life. Patients experience 40+ symptoms across multiple organ systems, often seeing multiple providers before receiving effective care. Clinicians must interpret large volumes of subjective symptom information, wearable data, and treatment history--but today that information is fragmented across patient notes, apps, intake forms, and electronic health records. As a result, menopause visits generate more patient-reported data than almost any other clinical encounter, yet most of that information never becomes structured clinical insight. Amissa solves this problem by transforming fragmented symptom data into structured clinical intelligence. The Amissa platform collects validated symptom assessments, patient-reported outcomes, wearable data, and structured logs, then organizes that information into visit-ready clinical reports and longitudinal insights that help clinicians understand symptom patterns, treatment response, and overall health trends over time. Clinicians receive EHR-ready summaries and analytics before each visit, enabling faster preparation, more informed clinical decision-making, and better documentation. Patients gain an easy way to track symptoms, visualize progress, and engage in their care. This infrastructure layer allows menopause care to become more data-driven, efficient, and scalable. Amissa benefits the entire healthcare ecosystem: * Patients gain better symptom understanding, clearer treatment progress, and more coordinated care * Clinicians save time on chart review and documentation while improving clinical decision-making * Health systems and practices improve workflow efficiency and capture appropriate reimbursement for complex menopause visits By organizing previously fragmented data, Amissa helps practices unlock the true economics of menopause care while improving patient outcomes. The company has received $3M+ in NIH funding and launched commercially in 2026 with early adoption across menopause specialists, private practices, and health systems. Amissa is now expanding partnerships with leading clinicians and academic medical centers to support research, clinical innovation, and scalable menopause care delivery. As demand for menopause care continues to grow rapidly, Amissa is building the data infrastructure and intelligence layer that modern menopause medicine requires.

Is this your company?